The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed Thursday, dampening expectations for the closely watched drug.
But Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying the data showed a “potential benefit.”
The summary said the Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group. Remdesivir was stopped early in 18 patients because of side effects.
Comments are closed.